Entyvio 300 MG vials
Ended Awarded Last action
- Contract number
- SPE2DR26FCRM1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $97,614
Award facts
- Contract value 100% obligated
- $97,613.60 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $97,613.60 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Entyvio 300 mg vials. The delivery order, issued on December 3, 2025, with an ultimate completion date of December 4, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This award represents a single delivery order under DMS Pharmaceutical Group's broader Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was established on November 13, 2025, with a $499.999 billion ceiling value and completion date of December 31, 2036.
DMS Pharmaceutical Group serves as a critical regional pharmaceutical supplier within the Defense Logistics Agency's $30.3 billion PPV-G GEN V acquisition strategy, which establishes multiple prime vendor contractors to support Department of Defense military healthcare facilities worldwide. The company's product portfolio encompasses branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals, with delivery orders issued without subcontractor relationships. The vendor's registration in the System for Award Management since July 2001 and demonstrated substantial federal contracting activity across multiple therapeutic categories position it as an established supplier within the federal pharmaceutical supply chain supporting the military medical system's recurring medical supply requirements globally.
Quick answers
Who was awarded contract SPE2DR26FCRM1?
SPE2DR26FCRM1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 3, 2025.
How much is contract SPE2DR26FCRM1 worth?
The government has obligated $97,614 on SPE2DR26FCRM1.
Is contract SPE2DR26FCRM1 an order under another contract?
Yes. SPE2DR26FCRM1 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRM1 competed?
The extent of competition for SPE2DR26FCRM1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award